{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:36:17Z","timestamp":1793050577433,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00198-026-08136-w","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:47:33Z","timestamp":1784123253000},"page":"2239-2251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of bisphosphonate pretreatment on bone mineral density gains and fracture outcomes with teriparatide: A systematic review and meta-analysis"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4859-9393","authenticated-orcid":false,"given":"Rimesh","family":"Pal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mainak","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urmila","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinjan","family":"Patra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay K.","family":"Bhadada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"8136_CR1","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1210\/jc.2009-1703","volume":"95","author":"JS Finkelstein","year":"2010","unstructured":"Finkelstein JS, Wyland JJ, Lee H, Neer RM (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95:1838\u20131845. https:\/\/doi.org\/10.1210\/jc.2009-1703","journal-title":"J Clin Endocrinol Metab"},{"key":"8136_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1620\/tjem.239.17","volume":"239","author":"M Kamimura","year":"2016","unstructured":"Kamimura M, Nakamura Y, Ikegami S et al (2016) Bisphosphonate pre-treatment diminishes the therapeutic benefits of teriparatide in Japanese osteoporotic patients. Tohoku J Exp Med 239:17\u201324. https:\/\/doi.org\/10.1620\/tjem.239.17","journal-title":"Tohoku J Exp Med"},{"key":"8136_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3109\/07853890.2012.742560","volume":"45","author":"A-M Koski","year":"2013","unstructured":"Koski A-M, L\u00f6yttyniemi E, V\u00e4\u00e4n\u00e4nen H et al (2013) The effectiveness of teriparatide in the clinical practice\u2014attenuation of the bone mineral density outcome by increasing age and bisphosphonate pretreatment. Ann Med 45:230\u2013235. https:\/\/doi.org\/10.3109\/07853890.2012.742560","journal-title":"Ann Med"},{"key":"8136_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00223-007-9066-5","volume":"81","author":"ET Middleton","year":"2007","unstructured":"Middleton ET, Steel SA, Doherty SM (2007) The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice. Calcif Tissue Int 81:335\u2013340. https:\/\/doi.org\/10.1007\/s00223-007-9066-5","journal-title":"Calcif Tissue Int"},{"key":"8136_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"8136_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"8136_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"8136_CR8","unstructured":"Wells G, Shea B, O\u2019Connell D, et al (2013) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses"},{"key":"8136_CR9","doi-asserted-by":"publisher","DOI":"10.13105\/wjma.v5.i4.80","volume":"5","author":"C Luchini","year":"2017","unstructured":"Luchini C, Stubbs B, Solmi M, Veronese N (2017) Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa scale. World J Meta-Anal 5:80. https:\/\/doi.org\/10.13105\/wjma.v5.i4.80","journal-title":"World J Meta-Anal"},{"key":"8136_CR10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"8136_CR11","doi-asserted-by":"publisher","unstructured":"Higgins JPT, Thomas J, Chandler J et al (2019) Cochrane handbook for systematic reviews of interventions, 1st edn. Wiley.\u00a0https:\/\/doi.org\/10.1002\/9781119536604","DOI":"10.1002\/9781119536604"},{"key":"8136_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11420-016-9537-1","volume":"13","author":"S-Y Kim","year":"2017","unstructured":"Kim S-Y, Zhang M, Bockman R (2017) Bone mineral density response from teriparatide in patients with osteoporosis. HSS J 13:171\u2013177. https:\/\/doi.org\/10.1007\/s11420-016-9537-1","journal-title":"HSS J"},{"key":"8136_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1359\/jbmr.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B, Martin SJ, Crans G, Pavo I (2004) Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate. J Bone Miner Res 19:745\u2013751. https:\/\/doi.org\/10.1359\/jbmr.040117","journal-title":"J Bone Miner Res"},{"key":"8136_CR14","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S Boonen","year":"2008","unstructured":"Boonen S, Marin F, Obermayer-Pietsch B et al (2008) Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis. J Clin Endocrinol Metab 93:852\u2013860. https:\/\/doi.org\/10.1210\/jc.2007-0711","journal-title":"J Clin Endocrinol Metab"},{"key":"8136_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/jbmr.3384","volume":"33","author":"P Geusens","year":"2018","unstructured":"Geusens P, Marin F, Kendler DL et al (2018) Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial. J Bone Miner Res 33:783\u2013794. https:\/\/doi.org\/10.1002\/jbmr.3384","journal-title":"J Bone Miner Res"},{"key":"8136_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00223-018-0437-x","volume":"103","author":"N Napoli","year":"2018","unstructured":"Napoli N, BenteL L, Ljunggren \u00d6 et al (2018) Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo\u00ae Observational Study (ExFOS). Calcif Tissue Int 103:359\u2013371. https:\/\/doi.org\/10.1007\/s00223-018-0437-x","journal-title":"Calcif Tissue Int"},{"key":"8136_CR17","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","volume":"94","author":"F Cosman","year":"2009","unstructured":"Cosman F, Wermers RA, Recknor C et al (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94:3772\u20133780. https:\/\/doi.org\/10.1210\/jc.2008-2719","journal-title":"J Clin Endocrinol Metab"},{"key":"8136_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1530\/EJE-11-0740","volume":"166","author":"F Jakob","year":"2012","unstructured":"Jakob F, Oertel H, Langdahl B et al (2012) Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo observational study. Eur J Endocrinol 166:87\u201397. https:\/\/doi.org\/10.1530\/EJE-11-0740","journal-title":"Eur J Endocrinol"},{"key":"8136_CR19","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1359\/jbmr.080506","volume":"23","author":"BM Obermayer-Pietsch","year":"2008","unstructured":"Obermayer-Pietsch BM, Marin F, McCloskey EV et al (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591\u20131600. https:\/\/doi.org\/10.1359\/jbmr.080506","journal-title":"J Bone Miner Res"},{"key":"8136_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jos.2016.11.022","volume":"22","author":"F Yoshiki","year":"2017","unstructured":"Yoshiki F, Nishikawa A, Taketsuna M et al (2017) Efficacy and safety of teriparatide in bisphosphonate-pretreated and treatment-naive patients with osteoporosis at high risk of fracture: post hoc analysis of a prospective observational study. J Orthop Sci 22:330\u2013338. https:\/\/doi.org\/10.1016\/j.jos.2016.11.022","journal-title":"J Orthop Sci"},{"key":"8136_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00774-009-0101-7","volume":"28","author":"C Keel","year":"2010","unstructured":"Keel C, Kraenzlin ME, Kraenzlin CA et al (2010) Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. J Bone Miner Metab 28:68\u201376. https:\/\/doi.org\/10.1007\/s00774-009-0101-7","journal-title":"J Bone Miner Metab"},{"key":"8136_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bonr.2015.11.001","volume":"4","author":"T Elraiyah","year":"2016","unstructured":"Elraiyah T, Ahmed AH, Wang Z et al (2016) Predictors of teriparatide treatment failure in patients with low bone mass. Bone Rep 4:17\u201322. https:\/\/doi.org\/10.1016\/j.bonr.2015.11.001","journal-title":"Bone Rep"},{"key":"8136_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bone.2018.07.013","volume":"116","author":"BL Langdahl","year":"2018","unstructured":"Langdahl BL, Silverman S, Fujiwara S et al (2018) Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: integrated analysis of 4 prospective observational studies. Bone 116:58\u201366. https:\/\/doi.org\/10.1016\/j.bone.2018.07.013","journal-title":"Bone"},{"key":"8136_CR24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf614","author":"BL Langdahl","year":"2025","unstructured":"Langdahl BL, Laursen N, M\u00e4kinen V et al (2025) Approach to the patient - transitions in osteoporosis therapy. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaf614","journal-title":"J Clin Endocrinol Metab"},{"key":"8136_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11914-025-00909-2","volume":"23","author":"MR McClung","year":"2025","unstructured":"McClung MR (2025) Sequential and long-term therapy for osteoporosis. Curr Osteoporos Rep 23:15. https:\/\/doi.org\/10.1007\/s11914-025-00909-2","journal-title":"Curr Osteoporos Rep"},{"key":"8136_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2217\/17455057.3.2.243","volume":"3","author":"JP Bilezikian","year":"2007","unstructured":"Bilezikian JP (2007) Anabolic therapy for osteoporosis. Womens Health (Lond) 3:243\u2013253. https:\/\/doi.org\/10.2217\/17455057.3.2.243","journal-title":"Womens Health (Lond)"},{"key":"8136_CR27","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S8756-3282(02)00735-4","volume":"30","author":"AM Parfitt","year":"2002","unstructured":"Parfitt AM (2002) Misconceptions (2): turnover is always higher in cancellous than in cortical bone. Bone 30:807\u2013809. https:\/\/doi.org\/10.1016\/S8756-3282(02)00735-4","journal-title":"Bone"},{"key":"8136_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/MED.0000000000000640","volume":"28","author":"R Pal","year":"2021","unstructured":"Pal R, Bhadada SK (2021) Bone health in diabetes: Indian perspective. Curr Opin Endocrinol Diabetes Obes 28:383\u2013389. https:\/\/doi.org\/10.1097\/MED.0000000000000640","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"8136_CR29","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf589","volume":"dgaf589","author":"TN Prasad","year":"2025","unstructured":"Prasad TN, Pal R, Bhadada SK et al (2025) Interim Effects of zoledronate, denosumab, or teriparatide on bone microarchitecture in type 2 diabetes: a pilot trial. J Clin Endocrinol Metab dgaf589:dgaf589. https:\/\/doi.org\/10.1210\/clinem\/dgaf589","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08136-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08136-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08136-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:02:04Z","timestamp":1793048524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08136-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8136"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08136-w","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Being a systematic review and meta-analysis, formal ethical clearance was not required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed written consent was obtained from all the participants.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rimesh Pal declares that he does not have any conflicts of interest. Mainak Banerjee declares that he does not have any conflicts of interest. Urmila Yadav declares that she does not have any conflicts of interest. Shinjan Patra declares that he does not have any conflicts of interest. Sanjay Kumar Bhadada declares that he does not have any conflicts of interest.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}